Tabi-Amponsah Adwoa Dansoa, Stewart Sarah, Hosie Graham, Stamp Lisa K, Taylor William J, Dalbeth Nicola
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
School of Clinical Sciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 0627, New Zealand.
Pharmaceuticals (Basel). 2023 May 23;16(6):779. doi: 10.3390/ph16060779.
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disease remission is a potential goal of urate-lowering therapy. In 2016, preliminary gout remission criteria were developed by a large group of rheumatologists and researchers with expertise in gout. The preliminary gout remission criteria were defined as: serum urate < 0.36 mmol/L (6 mg/dL); an absence of gout flares; an absence of tophi; pain due to gout < 2 on a 0-10 scale; and a patient global assessment < 2 on a 0-10 scale over a 12-month period. In this critical review, we describe the development of the preliminary gout remission criteria, the properties of the preliminary gout remission criteria, and clinical studies of gout remission in people taking urate-lowering therapy. We also describe a future research agenda for gout remission.
用于痛风管理的降尿酸疗法可降低血清尿酸水平、减少尿酸钠晶体沉积，并减轻痛风的临床症状，包括疼痛性和致残性痛风发作、慢性痛风性关节炎以及痛风石。因此，疾病缓解是降尿酸治疗的一个潜在目标。2016年，一大批痛风领域的风湿病学家和研究人员制定了初步的痛风缓解标准。初步的痛风缓解标准定义为：血清尿酸<0.36 mmol/L（6 mg/dL）；无痛风发作；无痛风石；痛风所致疼痛在0至10分的评分中<2分；以及患者整体评估在0至10分的评分中在12个月期间<2分。在这篇批判性综述中，我们描述了初步痛风缓解标准的制定、初步痛风缓解标准的特性，以及接受降尿酸治疗的人群中痛风缓解的临床研究。我们还描述了痛风缓解的未来研究议程。
